Sustainability of Brazilian policy for access to antiretroviral drugs
Main Author: | |
---|---|
Publication Date: | 2006 |
Other Authors: | , , |
Format: | Article |
Language: | por eng |
Source: | Revista de Saúde Pública |
Download full: | https://www.revistas.usp.br/rsp/article/view/32012 |
Summary: | OBJECTIVE: The expense of acquiring antiretroviral drugs in Brazil has given rise to debate about the sustainability of the policy of universal access to Aids medications, despite the evident benefits. The objective of this study was to analyze the evolution of the Ministry of Health's spending on acquiring antiretroviral drugs from 1998 to 2005, the determining factors and the medium-term sustainability of this policy (2006-2008). METHODS: The study on the evolution of spending on antiretrovirals included analysis of their prices, the year-by-year expenditure, the number of patients utilizing the medication, the mean expenditure per patient and the strategies for reducing the prices maintained during this period. To analyze the sustainability of the policy for access to antiretrovirals, the cost of acquiring the drugs over the period from 2006 to 2008 was estimated, along with the proportion of gross domestic product and federal health expenditure represented by this spending. The data were collected from the Ministry of Health, the Brazilian Institute for Geography and Statistics (IBGE) and the Ministry of Planning. RESULTS: The expenditure on antiretrovirals increased by 66% in 2005, breaking the declining trend observed over the period from 2000 to 2004. The main factors associated with this increase were the weakening of the national generics industry and the unsatisfactory results from the process of negotiating with pharmaceutical companies. CONCLUSIONS: The Brazilian policy for universal access is unsustainable at the present growth rates of the gross domestic product, unless the country compromises its investments in other fields. |
id |
USP-23_e12e758a50bddae2443c207bc4ee0ef2 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/32012 |
network_acronym_str |
USP-23 |
network_name_str |
Revista de Saúde Pública |
repository_id_str |
|
spelling |
Sustainability of Brazilian policy for access to antiretroviral drugs Sustentabilidade da política de acesso a medicamentos anti-retrovirais no Brasil Agentes anti-HIV^i1^seconoAgentes anti-HIV^i1^sprovisão e distribuiPolítica de saúde^i1^seconoProgramas nacionais de saúde^i1^seconoGastos em saúde^i1^sestatística e dados numériCustos de cuidados de saúdeCustos de medicamentosPlanejamento socioeconômicoEconomia FarmacêuticaBrasilAnti-HIV agents^i2^seconomAnti-HIV agentes^i2^ssupply & distributuHealth policy^i2^seconomNational health programs^i2^seconomHealth expenditures^i2^sstatistics & numerical dHealth care costsDrug costsSocioeconomic planningEconomics^i2^spharmaceutiBrazil OBJECTIVE: The expense of acquiring antiretroviral drugs in Brazil has given rise to debate about the sustainability of the policy of universal access to Aids medications, despite the evident benefits. The objective of this study was to analyze the evolution of the Ministry of Health's spending on acquiring antiretroviral drugs from 1998 to 2005, the determining factors and the medium-term sustainability of this policy (2006-2008). METHODS: The study on the evolution of spending on antiretrovirals included analysis of their prices, the year-by-year expenditure, the number of patients utilizing the medication, the mean expenditure per patient and the strategies for reducing the prices maintained during this period. To analyze the sustainability of the policy for access to antiretrovirals, the cost of acquiring the drugs over the period from 2006 to 2008 was estimated, along with the proportion of gross domestic product and federal health expenditure represented by this spending. The data were collected from the Ministry of Health, the Brazilian Institute for Geography and Statistics (IBGE) and the Ministry of Planning. RESULTS: The expenditure on antiretrovirals increased by 66% in 2005, breaking the declining trend observed over the period from 2000 to 2004. The main factors associated with this increase were the weakening of the national generics industry and the unsatisfactory results from the process of negotiating with pharmaceutical companies. CONCLUSIONS: The Brazilian policy for universal access is unsustainable at the present growth rates of the gross domestic product, unless the country compromises its investments in other fields. OBJETIVO: Os gastos com a aquisição de anti-retrovirais no Brasil têm suscitado debates sobre a sustentabilidade da política de acesso universal a medicamentos para Aids, a despeito de seus evidentes benefícios. O objetivo do estudo foi analisar, no período de 1998 a 2005, a evolução dos gastos do Ministério da Saúde do Brasil com a aquisição de anti-retrovirais e seus determinantes, assim como a sustentabilidade desta política a médio prazo (2006-2008). MÉTODOS: O estudo da evolução dos gastos com anti-retrovirais compreendeu a análise de seus preços, do dispêndio ano a ano, do número de pacientes que utilizam a medicação, do gasto médio por paciente e das estratégias para a redução de preços adotadas no período. No tocante à análise de sustentabilidade da política de acesso a anti-retrovirais foram estimadas as despesas com a aquisição de medicamentos no período de 2006 e 2008 e a participação desses gastos no Produto Interno Bruto e nas despesas federais com saúde. Os dados foram coletados do Ministério da Saúde, do Instituto Brasileiro de Geografia e Estatística e do Ministério do Planejamento. RESULTADOS: As despesas com anti-retrovirais aumentaram 66% em 2005, interrompendo a tendência de redução observada no período 2000-2004. Os principais fatores associados a esse aumento foram o enfraquecimento da indústria nacional de genéricos e os resultados insatisfatórios dos processos de negociação com empresas farmacêuticas. CONCLUSÕES: A política de acesso universal no Brasil não é sustentável com as atuais taxas de crescimento do Produto Interno Bruto, sem que o País comprometa investimentos em outras áreas. Universidade de São Paulo. Faculdade de Saúde Pública2006-04-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://www.revistas.usp.br/rsp/article/view/3201210.1590/S0034-89102006000800009Revista de Saúde Pública; Vol. 40 No. supl. (2006); 60-69 Revista de Saúde Pública; Vol. 40 Núm. supl. (2006); 60-69 Revista de Saúde Pública; v. 40 n. supl. (2006); 60-69 1518-87870034-8910reponame:Revista de Saúde Públicainstname:Universidade de São Paulo (USP)instacron:USPporenghttps://www.revistas.usp.br/rsp/article/view/32012/34039https://www.revistas.usp.br/rsp/article/view/32012/34040Copyright (c) 2017 Revista de Saúde Públicainfo:eu-repo/semantics/openAccessGrangeiro, AlexandreTeixeira, LucianaBastos, Francisco I.Teixeira, Paulo2012-07-08T22:58:31Zoai:revistas.usp.br:article/32012Revistahttps://www.revistas.usp.br/rsp/indexONGhttps://www.revistas.usp.br/rsp/oairevsp@org.usp.br||revsp1@usp.br1518-87870034-8910opendoar:2012-07-08T22:58:31Revista de Saúde Pública - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Sustainability of Brazilian policy for access to antiretroviral drugs Sustentabilidade da política de acesso a medicamentos anti-retrovirais no Brasil |
title |
Sustainability of Brazilian policy for access to antiretroviral drugs |
spellingShingle |
Sustainability of Brazilian policy for access to antiretroviral drugs Grangeiro, Alexandre Agentes anti-HIV^i1^secono Agentes anti-HIV^i1^sprovisão e distribui Política de saúde^i1^secono Programas nacionais de saúde^i1^secono Gastos em saúde^i1^sestatística e dados numéri Custos de cuidados de saúde Custos de medicamentos Planejamento socioeconômico Economia Farmacêutica Brasil Anti-HIV agents^i2^seconom Anti-HIV agentes^i2^ssupply & distributu Health policy^i2^seconom National health programs^i2^seconom Health expenditures^i2^sstatistics & numerical d Health care costs Drug costs Socioeconomic planning Economics^i2^spharmaceuti Brazil |
title_short |
Sustainability of Brazilian policy for access to antiretroviral drugs |
title_full |
Sustainability of Brazilian policy for access to antiretroviral drugs |
title_fullStr |
Sustainability of Brazilian policy for access to antiretroviral drugs |
title_full_unstemmed |
Sustainability of Brazilian policy for access to antiretroviral drugs |
title_sort |
Sustainability of Brazilian policy for access to antiretroviral drugs |
author |
Grangeiro, Alexandre |
author_facet |
Grangeiro, Alexandre Teixeira, Luciana Bastos, Francisco I. Teixeira, Paulo |
author_role |
author |
author2 |
Teixeira, Luciana Bastos, Francisco I. Teixeira, Paulo |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Grangeiro, Alexandre Teixeira, Luciana Bastos, Francisco I. Teixeira, Paulo |
dc.subject.por.fl_str_mv |
Agentes anti-HIV^i1^secono Agentes anti-HIV^i1^sprovisão e distribui Política de saúde^i1^secono Programas nacionais de saúde^i1^secono Gastos em saúde^i1^sestatística e dados numéri Custos de cuidados de saúde Custos de medicamentos Planejamento socioeconômico Economia Farmacêutica Brasil Anti-HIV agents^i2^seconom Anti-HIV agentes^i2^ssupply & distributu Health policy^i2^seconom National health programs^i2^seconom Health expenditures^i2^sstatistics & numerical d Health care costs Drug costs Socioeconomic planning Economics^i2^spharmaceuti Brazil |
topic |
Agentes anti-HIV^i1^secono Agentes anti-HIV^i1^sprovisão e distribui Política de saúde^i1^secono Programas nacionais de saúde^i1^secono Gastos em saúde^i1^sestatística e dados numéri Custos de cuidados de saúde Custos de medicamentos Planejamento socioeconômico Economia Farmacêutica Brasil Anti-HIV agents^i2^seconom Anti-HIV agentes^i2^ssupply & distributu Health policy^i2^seconom National health programs^i2^seconom Health expenditures^i2^sstatistics & numerical d Health care costs Drug costs Socioeconomic planning Economics^i2^spharmaceuti Brazil |
description |
OBJECTIVE: The expense of acquiring antiretroviral drugs in Brazil has given rise to debate about the sustainability of the policy of universal access to Aids medications, despite the evident benefits. The objective of this study was to analyze the evolution of the Ministry of Health's spending on acquiring antiretroviral drugs from 1998 to 2005, the determining factors and the medium-term sustainability of this policy (2006-2008). METHODS: The study on the evolution of spending on antiretrovirals included analysis of their prices, the year-by-year expenditure, the number of patients utilizing the medication, the mean expenditure per patient and the strategies for reducing the prices maintained during this period. To analyze the sustainability of the policy for access to antiretrovirals, the cost of acquiring the drugs over the period from 2006 to 2008 was estimated, along with the proportion of gross domestic product and federal health expenditure represented by this spending. The data were collected from the Ministry of Health, the Brazilian Institute for Geography and Statistics (IBGE) and the Ministry of Planning. RESULTS: The expenditure on antiretrovirals increased by 66% in 2005, breaking the declining trend observed over the period from 2000 to 2004. The main factors associated with this increase were the weakening of the national generics industry and the unsatisfactory results from the process of negotiating with pharmaceutical companies. CONCLUSIONS: The Brazilian policy for universal access is unsustainable at the present growth rates of the gross domestic product, unless the country compromises its investments in other fields. |
publishDate |
2006 |
dc.date.none.fl_str_mv |
2006-04-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/rsp/article/view/32012 10.1590/S0034-89102006000800009 |
url |
https://www.revistas.usp.br/rsp/article/view/32012 |
identifier_str_mv |
10.1590/S0034-89102006000800009 |
dc.language.iso.fl_str_mv |
por eng |
language |
por eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/rsp/article/view/32012/34039 https://www.revistas.usp.br/rsp/article/view/32012/34040 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2017 Revista de Saúde Pública info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2017 Revista de Saúde Pública |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Saúde Pública |
publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Saúde Pública |
dc.source.none.fl_str_mv |
Revista de Saúde Pública; Vol. 40 No. supl. (2006); 60-69 Revista de Saúde Pública; Vol. 40 Núm. supl. (2006); 60-69 Revista de Saúde Pública; v. 40 n. supl. (2006); 60-69 1518-8787 0034-8910 reponame:Revista de Saúde Pública instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Revista de Saúde Pública |
collection |
Revista de Saúde Pública |
repository.name.fl_str_mv |
Revista de Saúde Pública - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
revsp@org.usp.br||revsp1@usp.br |
_version_ |
1800221784538087424 |